Organovo Holdings Inc (NYSEMKT:ONVO) Shares Decline By 17.19%

928

Dallas, Texas 11/21/2013 (Financialstrend) – In Wednesday’s trading session, Organovo Holdings Inc (NYSEMKT:ONVO) dropped by 17.19%. The opening price of the shares was $9.18, which climbed to an intraday high of $9.28 and headed to close at $7.93. Around 17.09 million shares were exchanged on Wednesday while the average-volume of 6.82M shares were traded over a 30 day period. The 52-week low of Organovo Holdings Inc (NYSEMKT:ONVO) shares is $1.80 while the 52-week high is $13.65. The company has a market capitalization of $614.36 million.

About the company

Organovo Holdings Inc (NYSEMKT:ONVO) was previously the Real Estate Restoration & Rental Incorporated. The company was formed in 2007. It is a development-stage company. Organovo Holdings Inc (NYSEMKT:ONVO) has developed & is also commercializing a platform-technology that is used in the generation of the three-dimensional (3D) human-tissues that may be employed in drug-discovery & development, biological-research. It is also involved in developing and commercializing therapeutic-implants that can be used to treat damaged / degenerating tissues & organs.

On 28th December 2011, Real Estate Restoration & Rental, Inc. entered into an Agreement & Plan of Merger, after which RERR combined with its, hundred percent owned subsidiary, Organovo On 8th February 2012, Organovo Holdings Inc (NYSEMKT:ONVO) merged with Organovo Acquisition Corp. This is a 100%-owned subsidiary of Organovo. The Company surviving this merger became a 100%- owned subsidiary of Organovo Holdings. Resultant from this merger, Organovo Holdings Inc (NYSEMKT:ONVO) acquired the Organovo, Inc business.

It also has collaborative-research agreements with Pfizer, Inc. &United Therapeutic Corporation. As of 31st March 2012, it has 5 federal-grants, including Small Business Innovation-Research grants & has developed the NovoGen-MMX Bioprinter (the company’s 1st-generation 3D bioprinter). Organovo Holdings Inc (NYSEMKT:ONVO) is involved in developing specific 3D-human tissues that help Pfizer in discovering therapies in 2 different areas of interest and further the cause of science.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.